Jinshui Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinshui Yang has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Feng Huang
Department of Cardiology & Guangxi Key Laboratory Base of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention & Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
4 shared publications Jian Zhu
Department of Rheumatology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China
3 shared publications- Jianglin Zhang
Department of Rheumatology and Immunology The First Medical Center of Chinese PLA General Hospital 28 Fuxing Road, Haidian District Beijing 100853 China 301hospital.com.cn
3 shared publications - Kunpeng Li
Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
3 shared publications - Yiwen Wang
Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
3 shared publications Gui Luo
Department of Rheumatology, Chinese PLA General Hospital, Beijing, China
2 shared publications
Latest Publications
- 1 November 2022
- Published by Wolters Kluwer Health in Zhonghua Nei Ke Za Zhi
- Vol. 61 (11) , 1263-1268
[The application of clinical decision support system in gastrointestinal diseases].
- 1 November 2022
- Published by Wolters Kluwer Health in Zhonghua Nei Ke Za Zhi
- Vol. 61 (11) , 1263-1268
[The application of clinical decision support system in gastrointestinal diseases].
- Open Access
- 15 December 2021
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (15) , 1864-1866
Systemic lupus erythematosus following human papillomavirus 9-valent vaccination
An abstract is unavailable. This article is available as a PDF only.
- 15 December 2021
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (15) , 1864-1866
Open AccessSystemic lupus erythematosus following human papillomavirus 9-valent vaccination
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 25 February 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-11
Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study
Objectives. Ankylosing spondylitis (AS) is a chronic disease that decreases mobility, function, and quality of life. This study introduced the “Smart-phone SpondyloArthritis Management System” (SpAMS), an interactive mobile health (mHealth) tool designed for AS/spondyloarthritis (SpA) disease management and used SpAMS data to evaluate clinical characteristics of Chinese patients with AS. Methods. SpAMS integrates patient’s and physician’s portals in a smart phone application. The Chinese Ankylosing Spondylitis Prospective Imaging Cohort was launched using SpAMS in April 2016. Patient self-assessments were completed online at baseline and at every subsequent clinic visit. Physician-reported assessments and treatments were recorded by rheumatologists during each visit. Results. In total, 1201 patients with AS [mean (SD) age, 30.6 (8.7) years; male, 82.6%] were recruited. Mean (SD) disease duration was 8.4 (6.1) years. Past or current symptoms of acute anterior uveitis (AAU), psoriasis, and inflammatory bowel disease (IBD) were observed in 21.0%, 3.7%, and 9.4% of patients, respectively. AAU and IBD occurred significantly more in patients with symptom duration > 10 years. The most commonly used medications at baseline were nonsteroidal anti-inflammatory drugs (98.2%). Patients using tumour necrosis factor inhibitors accounted for 20.8%, and 66.4% of patients used conventional synthetic disease-modifying antirheumatic drugs. At baseline, 57.2% of patients had inactive disease (ID)/low disease activity (LDA); this rate significantly improved to 79.2% after a mean follow-up of 13.3 (5.9) months. Compared with relapsed patients, new achievers of ID/LDA underwent more online patient assessments (P < .001). Problems solved in SpAMS caused 29.1% of clinic visits to a tertiary hospital unnecessary. SpAMS saved an average of 5.3 hours and 327.4 RMB per person on traffic expenses; these expenses equalled 16% of the Chinese monthly disposable personal income. Conclusions. SpAMS is a time- and cost-saving disease management tool that can help patients with AS perform self-management and provide valuable data to clinicians.
- 25 February 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-11
Open AccessImprovement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study
Objectives. Ankylosing spondylitis (AS) is a chronic disease that decreases mobility, function, and quality of life. This study introduced the “Smart-phone SpondyloArthritis Management System” (SpAMS), an interactive mobile health (mHealth) tool designed for AS/spondyloarthritis (SpA) disease management and used SpAMS data to evaluate clinical characteristics of Chinese patients with AS. Methods. SpAMS integrates patient’s and physician’s portals in a smart phone application. The Chinese Ankylosing Spondylitis Prospective Imaging Cohort was launched using SpAMS in April 2016. Patient self-assessments were completed online at baseline and at every subsequent clinic visit. Physician-reported assessments and treatments were recorded by rheumatologists during each visit. Results. In total, 1201 patients with AS [mean (SD) age, 30.6 (8.7) years; male, 82.6%] were recruited. Mean (SD) disease duration was 8.4 (6.1) years. Past or current symptoms of acute anterior uveitis (AAU), psoriasis, and inflammatory bowel disease (IBD) were observed in 21.0%, 3.7%, and 9.4% of patients, respectively. AAU and IBD occurred significantly more in patients with symptom duration > 10 years. The most commonly used medications at baseline were nonsteroidal anti-inflammatory drugs (98.2%). Patients using tumour necrosis factor inhibitors accounted for 20.8%, and 66.4% of patients used conventional synthetic disease-modifying antirheumatic drugs. At baseline, 57.2% of patients had inactive disease (ID)/low disease activity (LDA); this rate significantly improved to 79.2% after a mean follow-up of 13.3 (5.9) months. Compared with relapsed patients, new achievers of ID/LDA underwent more online patient assessments (P < .001). Problems solved in SpAMS caused 29.1% of clinic visits to a tertiary hospital unnecessary. SpAMS saved an average of 5.3 hours and 327.4 RMB per person on traffic expenses; these expenses equalled 16% of the Chinese monthly disposable personal income. Conclusions. SpAMS is a time- and cost-saving disease management tool that can help patients with AS perform self-management and provide valuable data to clinicians.
- Open Access
- 1 January 2019
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 15 (3) , 700-705
Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China
Introduction To investigate the effect of dose maintenance, reduction, or discontinuation of the etanercept biosimilar Yisaipu (YSP) on early axial spondyloarthritis (axSpA) patients in remission with YSP 50 mg once weekly (QW). Material and methods Patients were enrolled in three groups:...
- 1 January 2019
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 15 (3) , 700-705
Open AccessFull dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China
Introduction To investigate the effect of dose maintenance, reduction, or discontinuation of the etanercept biosimilar Yisaipu (YSP) on early axial spondyloarthritis (axSpA) patients in remission with YSP 50 mg once weekly (QW). Material and methods Patients were enrolled in three groups:...
- Open Access
- 30 September 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-phone Management System: A Prospective Cohort Study (Preprint)
BACKGROUND Ankylosing spondylitis (AS) is a chronic disease that mainly affects the axial skeleton, leading to decreased mobility, function, and quality of life. With the advent of mobile health (mHealth) technologies, it is now possible to create more economical, sustainable, and user-friendly communication and health monitoring systems to improve the effectiveness of patient care and to gather real-world clinical data for clinical research. OBJECTIVE To introduce “smart-phone Spondyloarthritis Management System” (SpAMS), an interactive mobile health (mHealth) tool, specifically designed for longitudinal disease management and prospective ankylosing spondylitis (AS)/spondyloarthritis (SpA) and to evaluate the clinical profile of Chinese (AS) patients. METHODS SpAMS integrates the patient’s portal and the physician’s portal in a cell phone application. By using SpAMS, Chinese Ankylosing Spondylitis Prospective Imaging Cohort (CASPIC) was launched from April 2016. All patients fulfilled the 1984 modified New York criteria. Patient self-assessments were completed online at baseline and at every subsequent clinic visit. Physician-reported assessments and treatment regimens were recorded by rheumatologists during each visit. RESULTS In total, 1201 AS patients [mean (SD) age, 30.6 (8.7) years; male, 82.6%] were recruited. The mean (SD) disease duration was 8.4 (6.1) years. A history or current symptoms suggestive of acute anterior uveitis (AAU), psoriasis, and inflammatory bowel disease (IBD) were observed in 21.0%, 3.7%, and 9.4% of the patients, respectively. AAU and IBD were found significantly more in patients with a symptom duration > 10 years (31.1%, 12.5%, respectively). At the baseline visit, the most commonly used medications were non-steroidal anti-inflammatory drugs (NSAIDs) (98.2%). Patients using tumor necrosis factor inhibitors (TNFi) accounted for 20.8% of enrolled patients. Additionally, 66.4% of patients used conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs). At baseline, the percentage of patients with inactive disease (ID)/low disease activity (LDA) was 57.2%, and this value improved significantly to 79.2% after a mean follow-up of 13.3 (5.9) months. Compared with relapsed patients, new achievers of ID/LDA underwent more online patient assessments (P < .001). By solving problems in SpAMS, 29.1% of clinic visits were unnecessary and therefore time had been saved. At least an average of 5.3 hours and 327.4 RMB per person spent on traffic was saved through SpAMS. The saved traffic expenses were equal to 16% of the Chinese monthly disposable personal income. CONCLUSIONS SpAMS is a time- and cost-saving disease management tool, helping AS patients perform self-management and providing valuable data to clinicians. This is the first nationwide real-world study of AS patients in China who use mHealth technology, and our results contribute significantly to characterizing the clinical profiles of Chinese patients with AS.
- 30 September 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessImprovement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-phone Management System: A Prospective Cohort Study (Preprint)
BACKGROUND Ankylosing spondylitis (AS) is a chronic disease that mainly affects the axial skeleton, leading to decreased mobility, function, and quality of life. With the advent of mobile health (mHealth) technologies, it is now possible to create more economical, sustainable, and user-friendly communication and health monitoring systems to improve the effectiveness of patient care and to gather real-world clinical data for clinical research. OBJECTIVE To introduce “smart-phone Spondyloarthritis Management System” (SpAMS), an interactive mobile health (mHealth) tool, specifically designed for longitudinal disease management and prospective ankylosing spondylitis (AS)/spondyloarthritis (SpA) and to evaluate the clinical profile of Chinese (AS) patients. METHODS SpAMS integrates the patient’s portal and the physician’s portal in a cell phone application. By using SpAMS, Chinese Ankylosing Spondylitis Prospective Imaging Cohort (CASPIC) was launched from April 2016. All patients fulfilled the 1984 modified New York criteria. Patient self-assessments were completed online at baseline and at every subsequent clinic visit. Physician-reported assessments and treatment regimens were recorded by rheumatologists during each visit. RESULTS In total, 1201 AS patients [mean (SD) age, 30.6 (8.7) years; male, 82.6%] were recruited. The mean (SD) disease duration was 8.4 (6.1) years. A history or current symptoms suggestive of acute anterior uveitis (AAU), psoriasis, and inflammatory bowel disease (IBD) were observed in 21.0%, 3.7%, and 9.4% of the patients, respectively. AAU and IBD were found significantly more in patients with a symptom duration > 10 years (31.1%, 12.5%, respectively). At the baseline visit, the most commonly used medications were non-steroidal anti-inflammatory drugs (NSAIDs) (98.2%). Patients using tumor necrosis factor inhibitors (TNFi) accounted for 20.8% of enrolled patients. Additionally, 66.4% of patients used conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs). At baseline, the percentage of patients with inactive disease (ID)/low disease activity (LDA) was 57.2%, and this value improved significantly to 79.2% after a mean follow-up of 13.3 (5.9) months. Compared with relapsed patients, new achievers of ID/LDA underwent more online patient assessments (P < .001). By solving problems in SpAMS, 29.1% of clinic visits were unnecessary and therefore time had been saved. At least an average of 5.3 hours and 327.4 RMB per person spent on traffic was saved through SpAMS. The saved traffic expenses were equal to 16% of the Chinese monthly disposable personal income. CONCLUSIONS SpAMS is a time- and cost-saving disease management tool, helping AS patients perform self-management and providing valuable data to clinicians. This is the first nationwide real-world study of AS patients in China who use mHealth technology, and our results contribute significantly to characterizing the clinical profiles of Chinese patients with AS.
- Open Access
- 11 September 2018
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (2) , 465-475
Correlation between magnetic resonance imaging (MRI) findings and the new bone formation factor Dkk-1 in patients with spondyloarthritis
In recent years, MRI has been regarded as a major diagnostic tool for spondyloarthritis (SpA), and anti-TNF therapy has been widely confirmed as an effective treatment strategy. This study was designed to investigate the correlation between the secreted protein dickkopf-1 (Dkk-1) and abnormal findings on magnetic resonance imaging (MRI) through a prospective study of 30 cases of SpA. Thirty patients with active SpA were included, all treated with recombinant human tumor necrosis factor (TNF) receptor-antibody fusion protein (YiSaiPu) injection at 50 mg/week for 6 months. All patients were also examined for their clinical, serological, and imaging manifestations of the condition before and after treatment. In patients receiving TNF inhibitor treatment, the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and clinical activity indices BASDAI, BASFI, BASMI, ASDAS-CRP were significantly decreased (p < 0.01). Serum Dkk-1 concentration was also significantly decreased (p < 0.05), as were the scores of bone marrow edema of the sacroiliac joints and the spine (p < 0.05). The score of sacroiliac joint backfill was significantly increased (p < 0.05), and the baseline and changes in the serum Dkk-1 concentration were significantly correlated with the baseline and changes in spinal bone marrow edema levels. Inhibition of the level of serum Dkk-1 by TNF inhibitors may be the molecular basis for inhibiting the formation of new bone in SpA patients. In addition, spinal marrow edema may have significance for predicting new bone formation.
- 11 September 2018
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (2) , 465-475
Open AccessCorrelation between magnetic resonance imaging (MRI) findings and the new bone formation factor Dkk-1 in patients with spondyloarthritis
In recent years, MRI has been regarded as a major diagnostic tool for spondyloarthritis (SpA), and anti-TNF therapy has been widely confirmed as an effective treatment strategy. This study was designed to investigate the correlation between the secreted protein dickkopf-1 (Dkk-1) and abnormal findings on magnetic resonance imaging (MRI) through a prospective study of 30 cases of SpA. Thirty patients with active SpA were included, all treated with recombinant human tumor necrosis factor (TNF) receptor-antibody fusion protein (YiSaiPu) injection at 50 mg/week for 6 months. All patients were also examined for their clinical, serological, and imaging manifestations of the condition before and after treatment. In patients receiving TNF inhibitor treatment, the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and clinical activity indices BASDAI, BASFI, BASMI, ASDAS-CRP were significantly decreased (p < 0.01). Serum Dkk-1 concentration was also significantly decreased (p < 0.05), as were the scores of bone marrow edema of the sacroiliac joints and the spine (p < 0.05). The score of sacroiliac joint backfill was significantly increased (p < 0.05), and the baseline and changes in the serum Dkk-1 concentration were significantly correlated with the baseline and changes in spinal bone marrow edema levels. Inhibition of the level of serum Dkk-1 by TNF inhibitors may be the molecular basis for inhibiting the formation of new bone in SpA patients. In addition, spinal marrow edema may have significance for predicting new bone formation.
- 1 July 2015
- Vol. 54 (7) , 628-32
[The distinctive characteristics of ultrasonic imaging of enthesitis in spondyloarthritis patients].
To explore the distinctive ultrasonographic characters of enthesitis in patients with spondyloarthritis (SpA) and evaluate the diagnostic value of ultrasonography in SpA by comparing ultrasonography of enthesis in the lower limbs of patients with SpA, rheumatoid arthritis (RA) and osteoarthritis (OA). Entheses in the lower limbs (quadriceps tendon, proximal patellar ligament, distal patellar ligament, achilles tendon and plantar aponeurosis) were detected in SpA, RA, OA patients and health controls by ultrasonographic examination. A total of 46 SpA, 23 RA and 12 OA patients were enrolled in this study, with 26 SpA and 7 RA patients complaining of heel pain (P0.05). Sixty five (70.7%) sites of the distal patellar ligaments were abnormal in SpA group, while that were 19 (41.3%) in RA group (P<0.05) and 13 (54.2%) in OA group. Twenty six sites of tendon thickness and 22 sites of bone erosion in the distal patellar ligaments were found in SpA group, while only one site of each in RA group (P<0.05) and 4 sites of tendon thickness in OA group (P<0.05) were found.Tendon thickness, bursal synovitis and bone erosion coexisting in one distal patellar ligament indicated SpA, the sensitivity, specificity and the area under the curve (AUC) of which were 70.7%, 65.5% and 0.740, respectively. Tendon thickness and bone erosion of entheses were more likely the distinctive ultrasonographic characters of enthesitis in SpA patients. Tendon thickness, bursal synovitis and bone erosion in the distal patellar ligament could be an ideal tool for SpA diagnosis.
- 1 July 2015
- Vol. 54 (7) , 628-32
[The distinctive characteristics of ultrasonic imaging of enthesitis in spondyloarthritis patients].
To explore the distinctive ultrasonographic characters of enthesitis in patients with spondyloarthritis (SpA) and evaluate the diagnostic value of ultrasonography in SpA by comparing ultrasonography of enthesis in the lower limbs of patients with SpA, rheumatoid arthritis (RA) and osteoarthritis (OA). Entheses in the lower limbs (quadriceps tendon, proximal patellar ligament, distal patellar ligament, achilles tendon and plantar aponeurosis) were detected in SpA, RA, OA patients and health controls by ultrasonographic examination. A total of 46 SpA, 23 RA and 12 OA patients were enrolled in this study, with 26 SpA and 7 RA patients complaining of heel pain (P0.05). Sixty five (70.7%) sites of the distal patellar ligaments were abnormal in SpA group, while that were 19 (41.3%) in RA group (P<0.05) and 13 (54.2%) in OA group. Twenty six sites of tendon thickness and 22 sites of bone erosion in the distal patellar ligaments were found in SpA group, while only one site of each in RA group (P<0.05) and 4 sites of tendon thickness in OA group (P<0.05) were found.Tendon thickness, bursal synovitis and bone erosion coexisting in one distal patellar ligament indicated SpA, the sensitivity, specificity and the area under the curve (AUC) of which were 70.7%, 65.5% and 0.740, respectively. Tendon thickness and bone erosion of entheses were more likely the distinctive ultrasonographic characters of enthesitis in SpA patients. Tendon thickness, bursal synovitis and bone erosion in the distal patellar ligament could be an ideal tool for SpA diagnosis.
- 1 November 2014
- Vol. 53 (11) , 847-51
[The clinical characteristics of 26 cases of hypophosphatemia osteomalacia misdiagnosed as spondyloarthritis].
To study and summarize the clinical features of hypophosphatemia osteomalacia (HO) misdiagnosed as spondyloarthritis (SpA), aiming to analyze the reasons of misdiagnosis and improve the prognosis of such patients. A total of 26 cases of HO misdiagnosed as SpA were selected. Clinical features, laboratory tests, and image presentations were analyzed. Related literatures were reviewed. (1) Clinical characters: 26 patients were included (12 males and 14 females) with a median age of 38 years (range 20-60). The mean disease duration was 3.2 years (range 0.75 to 10 years). Of all the patients, 15 were diagnosed as tumor-induced HO, 4 were long-term oral adefovir dipivoxil-related HO, 3 were associated with Fanconi syndrome, 2 were related to hyperparathyroidism, while 2 were Sjogren's syndrome complicated with renal tubular acidosis. All of the 26 patients presented with low back pain including 15 with night pain. The time of morning stiffness was about 30 minutes. Non-steroidal anti-inflammatory drugs were given to each patient whereas with poor efficacy, neither did other agents work well, such as glucocorticoids, disease modifying anti-rheumatic drugs and biologics. (2) LABORATORY FINDINGS: the platelet count and inflammatory markers such as erythrocyte sedimentation rate, C-reactive protein (CRP) were usually normal. The level of serum calcium was normal or slightly lower, nevertheless, all patients had hypophosphatemia and increased level of alkaline phosphatase (ALP). Patients with adefovir dipivoxil-related HO, Fanconi syndrome or Sjogren's syndrome complicated with renal tubular acidosis were characterized by hypokalemia, hyperchloremia and alkaline urine. Patients with hyperparathyroidism had elevated parathyroid hormone (PTH). Positive antinuclear antibodies (ANA) (titer ≥ 1: 320), anti-SSA/SSB antibodies were found in patients with Sjogren's syndrome. (3) Radiographic features: sacroiliac joint lesions were found in X-ray, CT, positron emission tomography (PET-CT) or MRI, however the lesions in sacrum or ilium were predominant rather than in joints. Abnormal bone imaging in ribs, long bones and soft tissues in addition to joints could be detected by bone scintigraphy. HO is not uncommon in daily practice. Besides SpA, other diseases should be considered in the setting of low-back pain and diseased sacroiliac joints. Comprehensive screening of bone metabolic parameters contributes to the timely diagnosis of HO.
- 1 November 2014
- Vol. 53 (11) , 847-51
[The clinical characteristics of 26 cases of hypophosphatemia osteomalacia misdiagnosed as spondyloarthritis].
To study and summarize the clinical features of hypophosphatemia osteomalacia (HO) misdiagnosed as spondyloarthritis (SpA), aiming to analyze the reasons of misdiagnosis and improve the prognosis of such patients. A total of 26 cases of HO misdiagnosed as SpA were selected. Clinical features, laboratory tests, and image presentations were analyzed. Related literatures were reviewed. (1) Clinical characters: 26 patients were included (12 males and 14 females) with a median age of 38 years (range 20-60). The mean disease duration was 3.2 years (range 0.75 to 10 years). Of all the patients, 15 were diagnosed as tumor-induced HO, 4 were long-term oral adefovir dipivoxil-related HO, 3 were associated with Fanconi syndrome, 2 were related to hyperparathyroidism, while 2 were Sjogren's syndrome complicated with renal tubular acidosis. All of the 26 patients presented with low back pain including 15 with night pain. The time of morning stiffness was about 30 minutes. Non-steroidal anti-inflammatory drugs were given to each patient whereas with poor efficacy, neither did other agents work well, such as glucocorticoids, disease modifying anti-rheumatic drugs and biologics. (2) LABORATORY FINDINGS: the platelet count and inflammatory markers such as erythrocyte sedimentation rate, C-reactive protein (CRP) were usually normal. The level of serum calcium was normal or slightly lower, nevertheless, all patients had hypophosphatemia and increased level of alkaline phosphatase (ALP). Patients with adefovir dipivoxil-related HO, Fanconi syndrome or Sjogren's syndrome complicated with renal tubular acidosis were characterized by hypokalemia, hyperchloremia and alkaline urine. Patients with hyperparathyroidism had elevated parathyroid hormone (PTH). Positive antinuclear antibodies (ANA) (titer ≥ 1: 320), anti-SSA/SSB antibodies were found in patients with Sjogren's syndrome. (3) Radiographic features: sacroiliac joint lesions were found in X-ray, CT, positron emission tomography (PET-CT) or MRI, however the lesions in sacrum or ilium were predominant rather than in joints. Abnormal bone imaging in ribs, long bones and soft tissues in addition to joints could be detected by bone scintigraphy. HO is not uncommon in daily practice. Besides SpA, other diseases should be considered in the setting of low-back pain and diseased sacroiliac joints. Comprehensive screening of bone metabolic parameters contributes to the timely diagnosis of HO.